rare connect
Hope in the Lab: MSK Research Sheds Light on ECD and the Brain
A newly published study featured in the March 26, 2025, Memorial Sloan Kettering Cancer Center (MSK) Research Highlights offers important insight into how Erdheim-Chester Disease (ECD) and similar histiocytic disorders may affect the brain. This study brings a message of hope: basic science research is actively being performed to understand the underlying biology of ECD — and that knowledge could help prevent damage before it becomes irreversible.
The research paper, published in the journal Neuron, includes several authors who are actively involved in studying Erdheim-Chester Disease. Among them are Dr. Julien Haroche (Hôpital Pitié-Salpêtrière in Paris), and Dr. Eli Diamond (MSK), both leading clinician-scientists known for their dedication to ECD research and care. The work also involved other scientists who are studying ECD, reflecting a growing and collaborative global effort to understand this rare disease at the cellular level.
This study focused on how specific genetic mutations — particularly those in the MAPK pathway, such as BRAFV600E — alter the behavior of immune cells. These changes can potentially drive inflammation and damage in the central nervous system (CNS). The findings reinforce what patients and physicians have long observed: that ECD can have neurological effects, including balance issues, memory problems, and hormone imbalances. Importantly, the research suggests that these brain changes may begin long before symptoms appear — opening up a therapeutic window where early intervention might prevent long-term harm.
“As more is learned, it appears the long preclinical stage represents a therapeutic window before irreversible damage is done.” — MSK Research Highlights
This work is highly technical, but its implications are clear: deeper understanding of ECD at the molecular level will lead to better diagnostics, earlier detection, and hopefully more effective treatments in the future.
Read the full scientific article in Neuron (note: technical content):
https://www.cell.com/action/showPdf?pii=S0896-6273%2825%2900120-5
Read the MSK press summary:
MSK Research Highlights – March 26, 2025
As an organization committed to supporting research, education, and awareness, the ECD Global Alliance applauds this dedicated team of scientists for continuing to unravel the mysteries of Erdheim-Chester Disease. Every discovery moves us one step closer to improved outcomes and quality of life for those affected.
The Erdheim-Chester Disease Global Alliance (ECDGA) does not provide medical advice, diagnoses, or treatments. All content is for informational purposes only. Please consult with a healthcare provider for medical concerns.
